ACUTE MYELOGENOUS LEUKEMIA (AML) DUE TO THERAPY

Clinical trials for ACUTE MYELOGENOUS LEUKEMIA (AML) DUE TO THERAPY explained in plain language.

Never miss a new study

Get alerted when new ACUTE MYELOGENOUS LEUKEMIA (AML) DUE TO THERAPY trials appear

Sign up with your email to follow new studies for ACUTE MYELOGENOUS LEUKEMIA (AML) DUE TO THERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New drug duo tested in Tough-to-Treat blood cancers

Disease control Ongoing

This study is testing whether combining two drugs, CPX-351 and glasdegib, is safe and effective for adults with specific types of acute myeloid leukemia (AML) who have not yet received treatment. The main goal is to see how many patients are still in remission and event-free six …

Matched conditions: ACUTE MYELOGENOUS LEUKEMIA (AML) DUE TO THERAPY

Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Disease control

Last updated Apr 01, 2026 14:42 UTC

ACUTE MYELOGENOUS LEUKEMIA (AML) DUE TO THERAPY

Get alerted when new ACUTE MYELOGENOUS LEUKEMIA (AML) DUE TO THERAPY trials appear

New drug duo tested in Tough-to-Treat blood cancers